88 related articles for article (PubMed ID: 16972762)
1. Inhibition of ovarian tumor growth by gene therapy with recombinant soluble vascular endothelial growth factor receptor 2.
Wu Y; Li ZY; Zhao X; Kan B; Wei YQ
Hum Gene Ther; 2006 Sep; 17(9):941-8. PubMed ID: 16972762
[TBL] [Abstract][Full Text] [Related]
2. Gene therapeutic exploration: retrovirus-mediated soluble vascular endothelial growth factor receptor-2 (sFLK-1) inhibits the tumorigenicity of S180, MCF-7, and B16 cells in vivo.
Kou B; Li Y; Shi Y; Xia J; Wang X; Wu S
Oncol Res; 2005; 15(5):239-47. PubMed ID: 16261843
[TBL] [Abstract][Full Text] [Related]
3. Efficient inhibition of ovarian cancer growth and prolonged survival by transfection with a novel pro-apoptotic gene, hPNAS-4, in a mouse model. In vivo and in vitro results.
Yang F; Li Z; Deng H; Yang H; Yan F; Qian Z; Chen L; Wei Y; Zhao X
Oncology; 2008; 75(3-4):137-44. PubMed ID: 18824876
[TBL] [Abstract][Full Text] [Related]
4. Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels.
Yang F; Gou M; Deng H; Yi T; Zhong Q; Wei Y; Zhao X
Oncol Rep; 2012 Aug; 28(2):668-76. PubMed ID: 22684947
[TBL] [Abstract][Full Text] [Related]
5. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of corneal neovascularization by recombinant adenovirus-mediated sFlk-1 expression.
Yu H; Wu J; Li H; Wang Z; Chen X; Tian Y; Yi M; Ji X; Ma J; Huang Q
Biochem Biophys Res Commun; 2007 Oct; 361(4):946-52. PubMed ID: 17692288
[TBL] [Abstract][Full Text] [Related]
7. [Tumor targeting gene transfer mediated by electroporation for growth suppression of retinoblastoma in vivo].
Wang XL; Wang F; Wu JH; Yi MY; Xu P; Zhao XF; Xue YH; Huang Q
Zhonghua Yan Ke Za Zhi; 2005 Oct; 41(10):900-4. PubMed ID: 16271175
[TBL] [Abstract][Full Text] [Related]
8. Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice.
Schmitz V; Vilanueva H; Raskopf E; Hilbert T; Barajas M; Dzienisowicz C; Gorschlüter M; Strehl J; Rabe C; Sauerbruch T; Prieto J; Caselmann WH; Qian C
Gene Ther; 2006 Aug; 13(16):1198-205. PubMed ID: 16617302
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice.
Tseng JF; Farnebo FA; Kisker O; Becker CM; Kuo CJ; Folkman J; Mulligan RC
Surgery; 2002 Nov; 132(5):857-65. PubMed ID: 12464871
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
11. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
[TBL] [Abstract][Full Text] [Related]
12. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity.
Mahasreshti PJ; Kataram M; Wang MH; Stockard CR; Grizzle WE; Carey D; Siegal GP; Haisma HJ; Alvarez RD; Curiel DT
Clin Cancer Res; 2003 Jul; 9(7):2701-10. PubMed ID: 12855650
[TBL] [Abstract][Full Text] [Related]
13. [An experimental research on the combination treatment of sFLK-1 gene therapy combined with gamma knife].
Chen J; Wang ZR; Li H; Wei YQ; Wang W; Zhu B
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Sep; 37(5):708-11, 716. PubMed ID: 17037733
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.
Sallinen H; Anttila M; Narvainen J; Koponen J; Hamalainen K; Kholova I; Heikura T; Toivanen P; Kosma VM; Heinonen S; Alitalo K; Yla-Herttuala S
Mol Ther; 2009 Feb; 17(2):278-84. PubMed ID: 19050699
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.
Sopo M; Anttila M; Sallinen H; Tuppurainen L; Laurema A; Laidinen S; Hamalainen K; Tuunanen P; Koponen JK; Kosma VM; Heinonen S; Alitalo K; Yla-Herttuala S
Int J Cancer; 2012 Nov; 131(10):2394-401. PubMed ID: 22336998
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition of bladder cancer cell growth and angiogenesis by co-blockage of vascular endothelial growth factor and its receptor KDR].
Chen XL; Liu LC; Xu ZG; Li Z; Li RW; Gao RJ; Wang S; Zhang M; Guo H
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):578-82. PubMed ID: 19102933
[TBL] [Abstract][Full Text] [Related]
17. Efficient inhibition of an intraperitoneal xenograft model of human ovarian cancer by HSulf-1 gene delivered by biodegradable cationic heparin-polyethyleneimine nanogels.
Liu P; Gou M; Yi T; Xie C; Qi X; Zhou S; Deng H; Wei Y; Zhao X
Oncol Rep; 2012 Feb; 27(2):363-70. PubMed ID: 22086394
[TBL] [Abstract][Full Text] [Related]
18. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
Takayama K; Ueno H; Nakanishi Y; Sakamoto T; Inoue K; Shimizu K; Oohashi H; Hara N
Cancer Res; 2000 Apr; 60(8):2169-77. PubMed ID: 10786681
[TBL] [Abstract][Full Text] [Related]
19. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.
Mahasreshti PJ; Navarro JG; Kataram M; Wang MH; Carey D; Siegal GP; Barnes MN; Nettelbeck DM; Alvarez RD; Hemminki A; Curiel DT
Clin Cancer Res; 2001 Jul; 7(7):2057-66. PubMed ID: 11448924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
